QUALITY OF LTBI CARE: LTBI CASCADE OF CARE

JONATHON CAMPBELL, ON BEHALF OF HANNAH ALSDURF + DICK MENZIES McGILL INTERNATIONAL TB CENTRE

IMPORTANCE OF LATENT TB

Global estimates – 25% of world population have latent TB infection




Of these, about 10% will develop active TB



Meaning 1.7 billion infected and from these, 170 million will develop TB

IMPACT OF VARIOUS STRATEGIES ON TB TRENDS OVER NEXT 35 YEARS

(DYE, ET AL., ANN REV PUBL HEALTH 2013)



ASSESSING GAPS IN THE LTBI CASCADE OF CARE


What I often hear when I hear people talk about improving LTBI care...

50-60% of people complete LTBI treatment!

We need more people to complete treatment!!

Shorter regimens will solve our problems!!!

Cascade of care in LTBI management:TB contacts



CASCADE OF CARE IN LTBI – SYSTEMATIC REVIEW

373 articles identified from search

7 added from references of reviews

270 excluded after review of title and abstract

I I 0 full-text articles selected for review

58 studies included, describing 70 cohorts

748,571 participants

52 full-text articles excluded

14 were reviews

4 were RCTs

14 initial numbers of patients identified or screened not specified


17 final numbers of patients treated not specified

I no test positive specified

I duplicate publication

I could not obtain


KEY LOSSES ALONG THE LTBI CASCADE OF CARE



KEY LOSSES ALONG THE LTBI CASCADE OF CARE

So relative losses highest in completing Tx – BUT 70% of patients don't even start!!

Less than **20**% of eligible contacts completed preventive therapy



*Alsdurf, et al., Lancet Infect Dis 2016

BARRIERS ASSOCIATED WITH LOSSES - EXAMPLES

Step 2 - Not completing screening and testing

- Social situations impeding completion of screening (i.e. language/cultural barriers, feels too ill)
- Health-systems issues (i.e. hard to access clinic, long wait times, difficulties with insurance)

Step 4 – Not being referred or recommended for treatment

- Considered too old (older than 35 years)
- Low healthcare worker (HCW) knowledge about need for preventive therapy
- Social situations impeding treatment (i.e. substance abuse, fear of deportation or immigration status, recent release from jail/prison, no transportation)

SR/MA CONCLUSIONS

- Losses and drop-outs occur at every stage of care initial identification to completion of therapy
- 70% of all person who could benefit never even start. They will derive no benefit from better / shorter treatment!
- Latent TB care is a complex process!! A Cascade of care analysis can be helpful to pinpoint where the problems are occurring, and solutions needed
- Research is needed to determine factors associated with these losses
- But TB programs need to plan strategies to improve access to resources required for LTBI dx/tx, particularly among close household contacts of confirmed, pulmonary TB

EVALUATING AND (HOPEFULLY) FIXING THE LTBI CASCADE


ACT4TRIAL

ACT4: Pragmatic, cluster randomized trial (2015-2019)

- **5 countries**: Benin, Canada, Ghana, Indonesia, Vietnam
- Clusters: 24 health facilities


Objective: To evaluate a process to strengthen the latent TB Cascade of Care

- Standard evaluation Cascade analysis. Questionnaires to patients, contacts & HCWs
- Locally-selected solutions to address losses along the LTBI Cascade of Care
- Clinical in-service trainings were conducted with HCW at each site on a regular basis
- mTST: a mobile health approach for quality improvement and training of TST




Using a simple tool to assess the Cascade of Care in Latent TB


Cumulative proportion completing each cascade step



Percent of contacts completing each cascade step, as a percent of number completing previous step



Percent of the total lost that is attributed to each step of the cascade



Identifying and selecting solutions

- Impact of potential Solutions (IJTLD... under revision):
 - Scoping review of literature to identify potential "solutions"
 - What has been tried In Latent TB, Active TB (or other diseases if nothing found)
 - Identified their impact by step in Cascade.
 - i.e. How much improvement might be expected
- Meetings: with local TB programs, and the clinics
 - Review options for solutions, & evidence base for each
 - Select solutions: consider cost, feasibility, sustainability and potential impact (with help of modelling tool)
 - Approved by TB program, but finalized by clinic staff

ACT4: Cluster randomized RCT Site-specific Solutions — examples


To enhance initiation of LTBI therapy (Step 6-7):

- Provider education- regarding LTBI therapy. Prepare key messages. Study staff educate MDs and nurses (Brazil)
- Evening clinics- (for non-unionized new immigrants) (Calgary)
- Payments to health workers- for patients starting, and completing therapy. (Vietnam)
- Incentives- to patients who pick up prescriptions (Vancouver)

Brazil Cascade Experience (The Pilot Site)

- Bottlenecks appear in sequence as problems in the earlier steps were solved...
- Slides courtesy of Dr. Anete Trajman


1st Trimester results Problem Identified: no PPD and no TST training



Eval

Tx

2nd Trimester results Problem identified: Chest X-rays not available



Tx


Eval

Identified Assessment Assessment

3rd Trimester results Problem discovered: MDs did not prescribe INH treatment



4th Trimester Results: All problems identified and resolved (at least partially)




Eval

Tx

MOBILETST (mTST) - TRAINING TOOL

- Tuberculin Skin test (TST) is a relatively **simple test**, but requires careful training, as well as ongoing supervision.
- During ACT4 site visits in the fall 2017, our team found there were important errors in methods of TST administration.
- Objectives: I) To establish the best technical method to capture a photo of TST injection and reading, and 2) to estimate the accuracy for the measurement of TST injection and reading - using photos taken with smartphone (mTST)
- Results: Tool was validated and resource is available online to help train HCW
 - https://www.youtube.com/watch?v=S8gLaIPqvho





The bleb is measured immediately following TST administration by TB nurse



Photos are taken using the protocol and transmitted by email



The independent reviewers, measure the bleb using software (i.e. Microsoft Paint). Reviewers do not know onsite measurement(blinded)



The measurements are dichotomized "Injection is correct or incorrect"

<u>The mTST – a tool for quality</u> control for TST administration



Photos are taken and transmitted by email



TB nurse measures the induration using Ballpoint Pen Method. Reading in mm is transmitted to coordinator



The reviewers, read and answer the question "Is there induration present" Yes or No. Reviewers do not know onsite measurement(blinded)




Agreement of reviewers reports with nurse onsite measurements estimated by coordinator

mTST for Quality control of TST Reading




- All reviewers reported induration
- Onsite measurement: 70 mm


EXAMPLE OF LTBI CASCADE ANALYSIS – VIETNAM (courtesy Dr Buu)



Setting: 5 intervention districts in 2 Provinces in Central Vietnam (Da Nang and Quang Nam)

LOCAL SOLUTIONS - VIETNAM






Gap I: Identifying eligible contacts

Solution: Health educational materials for community regarding LTBI **Rationale**: With appropriate knowledge, the community will cooperate well with the health service in practice for LTBI management

IMPROVEMENT IN CASCADE IN LTBI MANAGEMENT WITH ACT4 INTERVENTIONS - FROM 2/4/2018 – 30/9/2018 (courtesy Dr Buu)



HHCs corresponding to 240 index TB patients

Example from Denver: Improving the latent TB cascade: clinic dashboard (courtesy Dr B Burman)





Digging deeper — reasons for drop-offs in the clinic latent TB cascade (courtesy Dr B Burman)



ReasonsTreatment Not Offered

Previously treated	33	
Unknown	6	
Other (specify)	5	
Pregnancy	5	
Age	2	
Risk of toxicity	1	
		0% 20% 40% 60%

ReasonsTreatment Declined

Perceived low risk	14		
Other	6		
Other patient preference	3		
Concern for side effects	2		
Need for regular follow-up	2		
Pregnancy	2		
		0%	40%

ReasonsTreatment Discontinued

		_	
Lost to care	61		
Unknown	9		
Adverse event	4		
Patient choice	4		
Pregnancy	3		
Not LTBI	1		
Transferred care	1		
		0%	50%

Need to improve data systems – previously treated patients should be classified as not needing treatment Need to work on patient/community education about TB risk

Need to decrease losses prior to treatment completion

HUMAN RESOURCE REQUIREMENTS TO IMPROVE QUALITY OF LTBI CARE


HUMAN RESOURCE REQUIREMENTS TO IMPROVE QUALITY OF LTBI CARE


- Estimate the human resource requirements to improve the quality of LTBI care at study sites
- To estimate the average HCW time spent on specific work tasks associated with each step in the LTBI Cascade of Care
- To calculate the change in personnel time spent on LTBI pre- and post-LTBI-strengthening activities

METHODS

- Used "Time and motion" (TAM) methods
- Follow HCW throughout a full, typical workday with continuous, direct observation
 - Write down every minute of work activity
 - Record time in pre-specified categories of activities
 - Break/pause time was removed from analysis important that HCW know they aren't being monitored for time spent on breaks

TIME SPENT ON PATIENT CARE - BY DIAGNOSIS





HCW TIME SPENT ON PATIENT ENCOUNTERS AT EACH STEP OF THE LTBI CASCADE OF CARE

LTBI Cascade of Care Steps**	Number of HCW performing each Step on TAM day	Total number of patient encounters with HCW at each Step on TAM day	Mean time spent on each Step (Std. Dev.)	Median time spent on each Step (IQR)
I. Identification of contacts	33	73	10.5 (10.4)	6.0 (2-16)
High Income ¹	20	39	14.0 (11.2)	12.0 (5-21)
LMIC ²	13	34	6.6 (8.0)	2.5 (2-7)
2. Place TST ³	22	64	8.1 (7.5)	5.5 (2-12)
High Income	13	32	13.1 (7.1)	11.0 (9-15)
LMIC	9	32	3.1 (3.4)	2.0 (2-4)
3. Read TST ³	17	59	6.4 (6.1)	4.0 (2-9)
High Income	П	22	11.9 (6.9)	10.5 (8-14)
LMIC	6	37	3.2 (1.6)	3.0 (2-4)

HCW TIME* SPENT ON PATIENT ENCOUNTERS AT EACH STEP OF THE LTBI CASCADE OF CARE


LTBI Cascade of Care Steps	Number of HCW performing each Step on TAM day	Total number of patient encounters with HCW at each Step on TAM day	Mean time spent on each Step (Std. Dev.)	Median time spent on each Step (IQR)
4. Conduct Medical Evaluation	43	116	12.1 (7.8)	11.0 (6-16)
High Income	33	90	13.0 (7.9)	12.0 (7-17)
LMIC	10	26	9.0 (6.6)	7.5 (2-15)
5. Recommend and discuss LTBI treatment	42	143	10.8 (8.5)	9.0 (4-13)
High Income	34	92	13.9 (8.9)	11.0 (8-18)
LMIC	8	51	5.3 (3.5)	4.0 (4-5)
6. LTBI treatment follow-up	56	276	9.3 (9.5)	6.0 (2-12)
High Income	44	191	12.0 (9.9)	9.0 (5-16)
LMIC	12	85	3.4 (4.4)	2.0 (1-5)

CONCLUSIONS

- I 0% increase in proportion of HCW time spent on LTBI-related activities as a result of LTBI programme strengthening
- BUT --- Time is taken away from active TB patient care activities (10% decrease in time on care for these type of patients)
 - HCW's in the same program had to shift work tasks as no staff were added
- TAMs provide a quantification of the ADDITIONAL HCW time required to expand LTBI services
 - To expand LTBI services need added staffing to perform these work tasks

LANCET GLOBAL HEALTH COMMISSION FRAMEWORK

- ACT4 addressed multiple components of the Lancet Global Health Commission's Framework including:
 - Workforce requirements:
 - Evaluated through the use of TAM studies
 - Tools:
 - Site evaluation of the LTBI Cascade of Care
 - Questionnaires used to identify barriers to LTBI care
 - Trainings for HCW using a mobile health technology (mTST) for placing and reading TST



*Kruk, et al. Lancet Global Health, 2018

QUESTIONS?

- ▶ My special thanks to Hannah Alsdurf for this impressive body of work.
- ► Special **THANKS!** to the ACT4 teams involved in data collection:
- ► Coordinating Center: Dr. Dick Menzies, Dr. Olivia Oxlade, Dr. Federica Fregonese, Chantal Valiquette
- ▶ **Benin**: Dr. Menonli Adjobimey, Lydia Yaha
- ► Canada: Nancy Bedingfield, Catherine Paulsen, Kamila Romanowski, Leslie Chiang, Saeedeh Moayedi Nia
- ► Ghana: Dr. Joseph Obeng, Daniel Boafo
- ▶ Indonesia: Dr. Rovina Ruslami, Dr. Panji Hadisoemarto, Isni Aini
- ▶ Vietnam: Dr. Thu Anh Nguyen, Dr. Tran Buu

The ACT4 trial is supported by the Canadian Institutes of Health Research Grant #FND331745







